Recent developments in positive psychology and spiritual practices suggest a nuanced pathway to enhancing psychological well-being through the cultivation of mindfulness, interoception, and balanced dual emotions. This article explores the conceptual progression from mindfulness to interoception, further leading to an understanding of internal values and the strategic balancing of the dual emotions of silence and happiness. Mindfulness, defined as the non-judgmental focus on the present moment. Interoception, or the awareness of internal body sensations, complements mindfulness by enhancing self-regulation. The integration of silence and happiness as dual emotions contributes to mental clarity which is crucial for reducing symptoms of anxiety and depression. Happiness, associated with positive social interactions and compassion, plays a critical role in the promotion of relational well-being. By maintaining a balance between these emotions, individuals may experience enhanced well-being through improved hormonal balance and psychological resilience. Supported by spiritual practices that emphasize egolessness and contentment, this model proposes that mindfulness, interoception, and dual emotion management can synergistically foster a health-promoting environment, both psychologically and physiologically. This research involving development of Heal-thy Life Spiritual Psychology Assessment Scale (HLSPAS) aims to synthesize these elements into a coherent model that contributes to the broader understanding of psychological well-being, drawing from spiritual experience and practice in these areas.
Overweight and obesity are concerns among young adults. This double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of Phikud Tri-Phon (PTP), a traditional Thai herbal decoction comprising Aegle marmelos, Morinda citrifolia, and Coriandrum sativum, for weight management in Thai females. Forty females aged 18–22 years with a body mass index (BMI) of 23.0–24.9 kg/m2 were randomly assigned to receive 150 mL of PTP decoction or a herbal-style placebo control twice daily for 6 weeks. Body composition, obesity-related indices, lipid profiles, and kidney and liver function markers were assessed at baseline and after the intervention. Per-protocol analyses included 17 participants in the PTP group and 16 in the placebo group. No statistically significant between-group differences were observed in body composition, obesity-related indices, lipid profiles, or kidney and liver biochemical markers after 6 weeks (p > 0.05). Although a device-derived metric of obesity degree decreased within the PTP group (p = 0.021), this change did not differ significantly from that of the placebo group (p = 0.894). No clinically meaningful between-group safety differences were identified during the 6-week study period.